Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours

Iman El-Hariry, Massimo Pignatelli, Nicholas Lemoine

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Acidic and basic fibroblast growth factors (FGF-1 and FGF-2) are mitogenic polypeptides that may play a role in autocrine and paracrine growth control of malignant tumours. We have examined the expression of FGF-1 and FGF-2 in a series of 41 colorectal tumours (24 adenomas, 17 adenocarcinomas) and 50 gastric adenocarcinomas (23 intestinal, 27 diffuse), using immunohistochemistry. Whereas the FGF-1 distribution was cytoplasmic, FGF-2 was restricted to the nuclei of the epithelial cells. FGF-1 immunoreactivity was detected in all samples (100 per cent), whereas FGF-2 immunoreactivity was seen in 17 adenomas (71 per cent), 13 colorectal carcinomas (76 per cent), and 29 gastric carcinomas (58 per cent). Compared with the normal mucosa, FGF-1 was overexpressed in 42 per cent of colorectal adenomas, 76 per cent of colorectal cancers, and 54 per cent of gastric cancers. Conversely, FGF-2 expression was reduced in 16 (66 per cent), 8 (47 per cent), and 40 (80 per cent) adenomas and colorectal and gastric samples, respectively. We found a significant correlation only between reduced FGF-2 and gastric tumour grade. These data indicate that FGF-1 overexpression occurs in a large proportion of human colorectal and gastric cancers. This may play a role in the progression of these tumours. The topographic variation in FGF-2 expression between normal (nuclear) and tumour (cytoplasmic) cells implies a corresponding functional change that may in turn facilitate tumour growth.

Original languageEnglish
Pages (from-to)39-45
Number of pages7
JournalJournal of Pathology
Volume181
Issue number1
DOIs
Publication statusPublished - Jan 1997
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 1
Fibroblast Growth Factor 2
Adenoma
Colorectal Neoplasms
Neoplasms
Stomach
Stomach Neoplasms
Adenocarcinoma
Growth
Mucous Membrane
Epithelial Cells
Immunohistochemistry
Carcinoma
Peptides

Keywords

  • colorectal adenoma
  • colorectal carcinoma
  • FGF-1
  • FGF-2
  • gastric carcinoma
  • immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours. / El-Hariry, Iman; Pignatelli, Massimo; Lemoine, Nicholas.

In: Journal of Pathology, Vol. 181, No. 1, 01.1997, p. 39-45.

Research output: Contribution to journalArticle

@article{cb8d12c57d2145539edb0210474d69cd,
title = "Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours",
abstract = "Acidic and basic fibroblast growth factors (FGF-1 and FGF-2) are mitogenic polypeptides that may play a role in autocrine and paracrine growth control of malignant tumours. We have examined the expression of FGF-1 and FGF-2 in a series of 41 colorectal tumours (24 adenomas, 17 adenocarcinomas) and 50 gastric adenocarcinomas (23 intestinal, 27 diffuse), using immunohistochemistry. Whereas the FGF-1 distribution was cytoplasmic, FGF-2 was restricted to the nuclei of the epithelial cells. FGF-1 immunoreactivity was detected in all samples (100 per cent), whereas FGF-2 immunoreactivity was seen in 17 adenomas (71 per cent), 13 colorectal carcinomas (76 per cent), and 29 gastric carcinomas (58 per cent). Compared with the normal mucosa, FGF-1 was overexpressed in 42 per cent of colorectal adenomas, 76 per cent of colorectal cancers, and 54 per cent of gastric cancers. Conversely, FGF-2 expression was reduced in 16 (66 per cent), 8 (47 per cent), and 40 (80 per cent) adenomas and colorectal and gastric samples, respectively. We found a significant correlation only between reduced FGF-2 and gastric tumour grade. These data indicate that FGF-1 overexpression occurs in a large proportion of human colorectal and gastric cancers. This may play a role in the progression of these tumours. The topographic variation in FGF-2 expression between normal (nuclear) and tumour (cytoplasmic) cells implies a corresponding functional change that may in turn facilitate tumour growth.",
keywords = "colorectal adenoma, colorectal carcinoma, FGF-1, FGF-2, gastric carcinoma, immunohistochemistry",
author = "Iman El-Hariry and Massimo Pignatelli and Nicholas Lemoine",
year = "1997",
month = "1",
doi = "10.1002/(SICI)1096-9896(199701)181:1<39::AID-PATH711>3.0.CO;2-C",
language = "English",
volume = "181",
pages = "39--45",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours

AU - El-Hariry, Iman

AU - Pignatelli, Massimo

AU - Lemoine, Nicholas

PY - 1997/1

Y1 - 1997/1

N2 - Acidic and basic fibroblast growth factors (FGF-1 and FGF-2) are mitogenic polypeptides that may play a role in autocrine and paracrine growth control of malignant tumours. We have examined the expression of FGF-1 and FGF-2 in a series of 41 colorectal tumours (24 adenomas, 17 adenocarcinomas) and 50 gastric adenocarcinomas (23 intestinal, 27 diffuse), using immunohistochemistry. Whereas the FGF-1 distribution was cytoplasmic, FGF-2 was restricted to the nuclei of the epithelial cells. FGF-1 immunoreactivity was detected in all samples (100 per cent), whereas FGF-2 immunoreactivity was seen in 17 adenomas (71 per cent), 13 colorectal carcinomas (76 per cent), and 29 gastric carcinomas (58 per cent). Compared with the normal mucosa, FGF-1 was overexpressed in 42 per cent of colorectal adenomas, 76 per cent of colorectal cancers, and 54 per cent of gastric cancers. Conversely, FGF-2 expression was reduced in 16 (66 per cent), 8 (47 per cent), and 40 (80 per cent) adenomas and colorectal and gastric samples, respectively. We found a significant correlation only between reduced FGF-2 and gastric tumour grade. These data indicate that FGF-1 overexpression occurs in a large proportion of human colorectal and gastric cancers. This may play a role in the progression of these tumours. The topographic variation in FGF-2 expression between normal (nuclear) and tumour (cytoplasmic) cells implies a corresponding functional change that may in turn facilitate tumour growth.

AB - Acidic and basic fibroblast growth factors (FGF-1 and FGF-2) are mitogenic polypeptides that may play a role in autocrine and paracrine growth control of malignant tumours. We have examined the expression of FGF-1 and FGF-2 in a series of 41 colorectal tumours (24 adenomas, 17 adenocarcinomas) and 50 gastric adenocarcinomas (23 intestinal, 27 diffuse), using immunohistochemistry. Whereas the FGF-1 distribution was cytoplasmic, FGF-2 was restricted to the nuclei of the epithelial cells. FGF-1 immunoreactivity was detected in all samples (100 per cent), whereas FGF-2 immunoreactivity was seen in 17 adenomas (71 per cent), 13 colorectal carcinomas (76 per cent), and 29 gastric carcinomas (58 per cent). Compared with the normal mucosa, FGF-1 was overexpressed in 42 per cent of colorectal adenomas, 76 per cent of colorectal cancers, and 54 per cent of gastric cancers. Conversely, FGF-2 expression was reduced in 16 (66 per cent), 8 (47 per cent), and 40 (80 per cent) adenomas and colorectal and gastric samples, respectively. We found a significant correlation only between reduced FGF-2 and gastric tumour grade. These data indicate that FGF-1 overexpression occurs in a large proportion of human colorectal and gastric cancers. This may play a role in the progression of these tumours. The topographic variation in FGF-2 expression between normal (nuclear) and tumour (cytoplasmic) cells implies a corresponding functional change that may in turn facilitate tumour growth.

KW - colorectal adenoma

KW - colorectal carcinoma

KW - FGF-1

KW - FGF-2

KW - gastric carcinoma

KW - immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=0031038857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031038857&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9896(199701)181:1<39::AID-PATH711>3.0.CO;2-C

DO - 10.1002/(SICI)1096-9896(199701)181:1<39::AID-PATH711>3.0.CO;2-C

M3 - Article

VL - 181

SP - 39

EP - 45

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -